Lilly Asia Ventures and ARCH Venture Partners Lead USD100m Series A for US- and China-Based Drug Developer SciNeuro
Source(s): AVCJ
Lilly Asia Ventures and ARCH Venture Partners led a USD100m Series A for SciNeuro Pharmaceuticals, a China- and US-based drug developer specializing in treatments for central nervous system disorders, with participation from Boyu Capital, General Atlantic, Sequoia Capital China, TF Capital, and Zoo Capital. Read more